Solutions for
Difficult-to-Treat Cancers

FLAG Therapeutics is a near-term clinical stage company focused on developing new small molecule therapeutics for difficult-to-treat cancers. FLAG-003, the company’s lead candidate for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG - a rare and fatal pediatric cancer) and glioblastoma multiform (GBM), is on-track to enter Phase 1 clinical development in early 2026 in children with DIPG.

3 Drug Discovery Platforms
FLAG-003 for DIPG + GBM
Investors

Recent News / Events

FLAG Therapeutics Secures Over $500,000 in Equity and Impact Funding from Venture and Mission-Driven Investors, Including Springhood Ventures, Kids Beating Cancer, The Musella Foundation, the AYJ Fund, Tough2gether Foundation and DDRFA

October 31, 2025

July 16, 2024

21st International Symposium on Pediatric Neuro-Oncology
Poster DIPG68: FLAG-003, A NOVEL, DUAL-ACTION THERAPEUTIC, DEMONSTRATES IN-VITRO ACTIVITYAGAINST DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

July 1, 2024

FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

Click here to view related abstract and poster